Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in EuropeNovartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing Share XTakeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europehttps://pharmaphorum.com/news/takeda-to-make-200m-loss-after-novartis-dry-eye-drug-hits-trouble-in-europe/
Bausch + Lomb buys US rights to Stada’s Lucentis biosimilarBausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches Share XBausch + Lomb buys US rights to Stada’s Lucentis biosimilarhttps://pharmaphorum.com/news/bausch-lomb-buys-us-rights-to-stadas-lucentis-biosimilar/
UK court imposes safety rules on off-label use of Avastin in wet-AMDBayer has said a new UK court ruling could limit off-label use of Roche’s Avastin in ophthalmology by Share XUK court imposes safety rules on off-label use of Avastin in wet-AMDhttps://pharmaphorum.com/news/uk-appeal-court-upholds-use-of-avastin/
First patient dosed in trial of Allergan/Editas’ CRISPR blindness drugA first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, Share XFirst patient dosed in trial of Allergan/Editas’ CRISPR blindness drughttps://pharmaphorum.com/news/first-patient-dosed-in-trial-of-allergan-editas-crispr-blindness-drug/
Novartis’ Beovu safety woes could cost billions of dollars, says analystThe launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several Share XNovartis’ Beovu safety woes could cost billions of dollars, says analysthttps://pharmaphorum.com/news/novartis-beovu-launch-could-be-hit-by-safety-warning/
More pressure on Bayer as EU approves Novartis’ Beovu in wet AMDThe market for ophthalmology drugs in Europe just got hotter with the approval of Novartis’ Beovu for neovascular Share XMore pressure on Bayer as EU approves Novartis’ Beovu in wet AMDhttps://pharmaphorum.com/news/more-pressure-on-bayer-as-eu-approves-novartis-beovu-in-wet-amd/
Verily plans digital ophthalmology joint venture with SantenVerily is planning a digital ophthalmology joint venture with Japan’s specialist in the field, Santen. The joint venture Share XVerily plans digital ophthalmology joint venture with Santenhttps://pharmaphorum.com/news/verily-plans-ophthalmology-joint-venture-with-santen/
ViGeneron to develop next-gen eye gene therapies after funding roundGermany’s ViGeneron is to advance development of its next-generation ophthalmology gene therapy pipeline after a series A financing Share XViGeneron to develop next-gen eye gene therapies after funding roundhttps://pharmaphorum.com/news/vigeneron-to-develop-next-gen-eye-gene-therapies/
Biogen signs marketing deal for two ophthalmology biosimilarsBiogen has gained rights to market two potential ophthalmology biosimilars in major markets including the US, Europe and Share XBiogen signs marketing deal for two ophthalmology biosimilarshttps://pharmaphorum.com/news/biogen-signs-marketing-deal-for-two-ophthalmology-biosimilars/
